Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

221
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
221
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

157
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
157
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

207
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
207
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

153
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
153
Amyloid Fibrils03:03

Amyloid Fibrils

6.1K
6.1K
Amyloid Fibrils03:03

Amyloid Fibrils

11.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic multimodal phenotyping in AL amyloidosis with cardiac involvement: the D-Amy-LIPHE study.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026
Same author

Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial.

Nature medicine·2026
Same author

Emotional Impact of Patient Death and Associated Psychological Distress in Cardiac Physicians.

JACC. Advances·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

Impact of the MonCœur smartphone application on self-care and quality of life in heart failure: The APPLIMONCOEUR randomized trial.

Archives of cardiovascular diseases·2026
Same author

Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.

European journal of heart failure·2026

Related Experiment Video

Updated: Nov 22, 2025

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.5K

[Cardiac amyloidosis].

Elsa Poullot1, Silvia Oghina2, Sarah Kalsoum1

  • 1Département de pathologie, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France; Centre français de référence de l'amylose cardiaque (CRAC), réseau Cardiogen, GHU Henri-Mondor, Assistance publique-Hôpitaux de Paris, Créteil, France.

Annales De Pathologie
|January 10, 2021
PubMed
Summary

Cardiac amyloidosis, primarily transthyretin and light chain types, has improved diagnostics and treatments. Targeted therapies have significantly enhanced patient prognosis in the last decade.

Keywords:
AL amyloidosisATTR amyloidosisAmylose ALAmylose ATTRAmylose cardiaqueBiopsie endomyocardiqueCardiac amyloidosisEndomyocardial biopsyMass spectrometrySpectrométrie de masseTransthyretinTransthyrétine

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.4K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.9K

Related Experiment Videos

Last Updated: Nov 22, 2025

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.5K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.4K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.9K

Area of Science:

  • Cardiology
  • Pathology
  • Medical Research

Background:

  • Cardiac amyloidosis involves abnormal protein deposits in the heart.
  • Transthyretin amyloidosis and light chain amyloidosis are the most prevalent forms.
  • Recent advancements have improved diagnosis and treatment outcomes.

Purpose of the Study:

  • To describe clinical manifestations of cardiac amyloidosis.
  • To outline the diagnostic approach for cardiac amyloidosis.
  • To detail the characteristics and treatments of common cardiac amyloidosis types, emphasizing amyloid typing.

Main Methods:

  • Review of clinical manifestations.
  • Description of diagnostic strategies.
  • Analysis of histopathological findings and amyloid typing.
  • Discussion of targeted therapies for specific amyloid types.

Main Results:

  • Improved diagnostic performance and typing accuracy for cardiac amyloidosis.
  • Significant enhancement in patient prognosis due to targeted therapies.
  • Identification of transthyretin and light chain amyloidosis as leading causes.

Conclusions:

  • Cardiac amyloidosis management has advanced significantly.
  • Accurate amyloid typing is crucial for effective, targeted treatment.
  • Improved prognosis is achievable with contemporary diagnostic and therapeutic strategies.